Intensity Therapeutics, Inc.

INTS

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001567264

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $14.1M
Warnings	dilution, thin data, distress not computable: degenerate inputs, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 27, 2026 231 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$3.39 2026-11-11; market equity $11.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRxSM discovery platform. Intratumoral ("IT") treatment, or treatment designed to contain a drug inside a tumor without spreading to the rest of the body, has been an objective of clinicians since discovery of chemotherapeutic agents.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 17.1						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(25.1%)	(6.6%)	17.1	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 62.5					
Twelve-month failure probability	2.34%	0.08%	89.0	247	2026-09-30
Altman Z double-prime	(13.31)	(0.35)	67.6	744	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	5.92x	2.95x	31.0	826	2025-12-31
Growth and financing, sleeve percentile 91.9					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 3					
Net share issuance, one year	318.4%	2.5%	91.9	627	2026-03-26

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 318.4%
Thin data	5 of 14 grade factors are computable; minimum is 7
Distress	CHS probability 2.337337%; universe top-decile threshold 2.222209%

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(81.5%)	(1.9%)	5
Distance from 52-week high	(79.0%)	(30.8%)	9
EBIT to enterprise value	not computable	(1.9%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.75	0.28	79
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.86)	(0.19)	5

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$8.5M
Operating cash flow, four quarters	-$9.1M
Months of runway	11.2
Days since last periodic filing	8 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$47,648

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$11.6M	2025-12-31	2026-03-27	10-K	26-000024
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$9.2M	2025-12-31	2026-03-27	10-K	26-000024
3	assets	us-gaap:Assets	$14.1M	2025-12-31	2026-03-27	10-K	26-000024
4	assets	us-gaap:Assets	$4.8M	2024-12-31	2026-03-27	10-K	26-000024
5	current assets	us-gaap:AssetsCurrent	$12.7M	2025-12-31	2026-03-27	10-K	26-000024
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.1M	2025-12-31	2026-03-27	10-K	26-000024
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$78.4M	2025-12-31	2026-03-27	10-K	26-000024
8	operating income	us-gaap:OperatingIncomeLoss	-$12.0M	2025-12-31	2026-03-27	10-K	26-000024
9	book equity	us-gaap:StockholdersEquity	$11.9M	2025-12-31	2026-03-27	10-K	26-000024
10	liabilities	us-gaap:Liabilities	$2.2M	2025-12-31	2026-03-27	10-K	26-000024
11	operating income	us-gaap:OperatingIncomeLoss	-$8.3M	2023-12-31	2025-03-13	10-K	25-000010
12	interest expense	us-gaap:InterestExpense	$305,000	2023-12-31	2024-03-14	10-K	24-011207
13	assets	us-gaap:Assets	$17.3M	2023-12-31	2025-03-13	10-K	25-000010
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,540,518	2026-03-26	2026-03-27	10-K	26-000024
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	15,180,945	2025-03-12	2025-03-13	10-K	25-000010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.